mRNA-Grippeimpfung zeigt im Versuch bessere Ergebnisse als herkömmlicher Impfstoff. Menschen, die die mRNA-Grippeimpfung erhielten, hatten 34,5 % weniger grippeähnliche Erkrankungen als diejenigen, die den üblichen Impfstoff erhielten. Dennoch ist die Genehmigung möglicherweise nicht einfach. Im August haben die USA fast 500 Millionen US-Dollar an Fördermitteln für die mRNA-Impfstoffforschung gestrichen.

I’ve linked to the news release in the post above. In this comment, for those interested, here’s the link to the peer reviewed journal article:

https://www.nejm.org/doi/full/10.1056/NEJMoa2416779

From the linked article:

**mRNA flu shot shows better results than traditional vaccine in trial**

Pfizer’s mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported.

The results, published Nov. 19 in The New England Journal of Medicine, suggest that mRNA technology may help improve protection in future flu seasons.

The Pfizer flu vaccine uses the same type of messenger RNA science that was used in the company’s COVID-19 shot.

More than 18,000 adults took part in the Phase 3 trial during the 2022-2023 flu season. Some received Pfizer’s mRNA flu shot, while the others received Fluzone, a standard seasonal flu vaccine.

Researchers found that **people who got the mRNA flu shot had 34.5% fewer flu-like illnesses than those who got Fluzone**. There were 57 cases in the mRNA group compared to 87 cases in the Fluzone group.

Nearly all were caused by two common influenza A strains: H3N2 and H1N1. The mRNA vaccine also protected against two B strains: Victoria and Yamagata.

The vaccine could be a „game-changer,“ Dr. Buddy Creech of Vanderbilt University Medical Center in Nashville, Tennessee told NBC News.

He noted that mRNA vaccines can be made faster, which could help scientists better match the shot to the strains that actually end up circulating each year.

**Even so, experts warn that approval may not come easily**. Several public officials have recently raised doubts about mRNA vaccines, and in August **the U.S. Department of Health and Human Services canceled nearly $500 million in funding for mRNA vaccine research**.